Speaker: Alan Haruo Bryce

0:00:36

The clinical impact of TRITON3 on the potential role of rucaparib in the future treatment of mCRPC

0:02:02

Unanswered questions regarding the use of PARP inhibitors for patients with mCRPC

0:02:59

TRITON3 interim OS results demonstrate superiority of rucaparib over docetaxel for mCRPC